Radioligand therapy is an innovative way to treat cancer using precision nuclear medicine. Treatment is personalized to specific tumors by leveraging a specific targeted method, known as a “theranostic” approach. This means that the specific radiotracers used to diagnose certain tumor characteristics can then be adapted to treat the cancer cells using specifically labeled radiopharmaceuticals. Through this two-pronged approach, patients are qualified for specifically targeted therapy via diagnostic molecular imaging, evaluating target expression in tumor lesions, allowing only those patients who might potentially benefit to receive the treatment.
Over the past 10 years, we have been developing radioligand therapy (RLT), a proven, exciting new modality that uses a precision medicine ‘You-treat-what-you-see’ approach. Our pre-clinical and clinical teams have been working to characterize and evaluate the efficacy and safety of this novel, targeted way to deliver radiotherapy in order to bring new solutions for cancer patients.
What is Radioligand Therapy?
Paving the way for personalized nuclear medicine
“Radioligand therapy is leading us to the future of nuclear medicine. Targeted radiation can destroy the tumor from the inside out, while minimizing effects on healthy tissues”
We are always looking to partner to develop novel therapies in this field. We recently granted exclusive global development and commercialization rights to ITM Isotope Technologies Munich SE for our first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452) and diagnostic imaging agent, Debio 0328 ([68Ga]Ga-DPI-4452) now known as ITM-91 and ITM-94D respectively, to target Carbonic Anhydrase IX (CA IX).
We plan to further exercise our RLT expertise through our dynamic pipeline unique business model that allows us to bridge the gap between innovative discoveries and worldwide patient reach.
How we're applying our expertise
Personalized Medicine
Our Translational Medicine team analyses tumors to identify biomarkers suitable for radioligand targeting
Clinical Development
In 2024, we coordinated with international RLT centers to launch the Phase 1/2 GaLuCi study evaluating our CA IX targeted radioligand
Partnering with Experts
We partner with biotech & pharmaceutical with radioligand therapy expertise to accelerate innovation for patients
Insights from our experts
Get Involved
Do you have a compound?
We scout for new, innovative pharmaceutical drug candidates to go through our full drug development value chain, from preclinical to registration.
Partner with us
Interested in one of our programs?
We are looking for out-licensing partners for all projects with a focus on our clinically advanced candidates.
Partner with us
Join our team
Developing innovative therapies for patients is in our DNA. Is it in yours too?
Seize The Opportunity